Can a lower dose of palbociclib work just as well for advanced breast cancer?
NCT ID NCT02630693
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 2 trial enrolled 180 women with ER-positive, HER2-negative advanced or metastatic breast cancer. Researchers compared two different dosing schedules of the targeted drug palbociclib (100 mg daily vs. 125 mg for 3 weeks on, 1 week off) combined with standard hormone therapy. The goal was to see if the lower daily dose could offer similar cancer control with fewer dose interruptions. The study measured progression-free survival and response rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Palbociclib (a targeted cancer drug) plus endocrine therapy (fulvestrant, tamoxifen, or an aromatase inhibitor)
- What this could lead to
- If successful, this could identify a better dosing schedule for palbociclib that maintains effectiveness while reducing side effects and dose delays.
- What could go wrong
- This is a phase 2 trial with only 180 participants, so results may not be definitive. The lower dose might be less effective, and the study does not test a new drug or cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1, Canada
-
BCCA - Abbotsford Centre
Abbotsford British Columbia, British Columbia, V2S 0C2, Canada
-
BCCA - Fraser Valley Cancer Centre
Surrey, British Columbia, V3V 1Z2, Canada
-
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
CHA-Hopital Du St-Sacrement
Québec, Quebec, G1S 4L8, Canada
-
CHUM - Hopital Notre-Dame
Montreal, Quebec, H2L 4M1, Canada
-
Cancer Centre of Southeastern Ontario at Kingston
Kingston, Ontario, K7L 5P9, Canada
-
Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, J1H 5N4, Canada
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
Dr. H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, A1B 3V6, Canada
-
Hopital du Sacre-Coeur de Montreal
Montreal, Quebec, H4J 1C5, Canada
-
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2, Canada
-
Lakeridge Health Oshawa
Oshawa, Ontario, L1G 2B9, Canada
-
Niagara Health System
St. Catharines, Ontario, L2S 0A9, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
QEII Health Sciences Centre
Halifax, Nova Scotia, B3H 1V7, Canada
-
Royal Victoria Regional Health Centre
Barrie, Ontario, L4M 6M2, Canada
-
Stronach Regional Health Centre at Southlake
Newmarket, Ontario, L3Y 2P9, Canada
-
The Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
The Moncton Hospital
Moncton, New Brunswick, E1C 6Z8, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
-
Windsor Regional Cancer Centre
Windsor, Ontario, N8W 2X3, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?